|
Synthego, a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions, has expanded its CRISPR solutions portfolio with the launch of GMP SpCas9, offering researchers a powerful solution to enhance CRISPR-based therapeutic development. The launch of GMP SpCas9 enables researchers to bundle the nuclease with IND-enabling or GMP sgRNAs into a convenient, unified package, optimizing processes and driving therapeutic progress.
Produced under certified cGMP manufacturing standards, GMP SpCas9, in combination with best-in-class GMP sgRNAs, provides researchers with a comprehensive CRISPR solution that ensures exceptional quality, consistency, and scalability required for therapeutic applications. Further supporting development, Synthego offers access to Drug Master Files (DMFs) with unified regulatory documentation for both GMP sgRNAs and GMP SpCas9, simplifying regulatory submission filings and reducing complexity.
“We are excited to expand our portfolio of best-in-class CRISPR solutions to include a GMP SpCas9 nuclease. With this addition, we now provide the highest quality CRISPR-based gene editing tools desired for human clinical studies, at a budget-friendly price. It is our continuing mission to democratize CRISPR at both the academic and clinical research phase without compromising on quality," said Jason Miller, chief commercial officer.
Through the launch of GMP SpCas9 and its seamless integration with GMP sgRNAs, Synthego continues to deliver cutting-edge CRISPR solutions that empower therapeutic developers to accelerate progress in CRISPR-based cell and gene therapies. Discover more about GMP SpCas9 and GMP sgRNAs by visiting the product page or contacting our experts to start your GMP project.
Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health.
|